Ifosfamide-Induced Encephalopathy in Relapsed Lymphoma: Report of Two Cases

Davin Takaryanto, Gusti Fungani Harti, Amaylia Oehadian

Abstract


Objective: Ifosfamide is a chemotherapeutic drug available for various malignancy, including lymphoma. Ifosfamide has adverse effects including myelosuppression, nephrotoxicity, hemorrhagic cystitis, and neurotoxicity. Encephalopathy is a severe manifestation of neurotoxicity due to ifosfamide, with an incidence of 10–40%. This study aimed to report two cases of ifosfamide-induced encephalopathy.

Case: This case studies reported two relapsed lymphoma patients with almost similar characteristics who received ifosfamide chemotherapy. The first case of 48-year-old woman with relapsed High-Grade B-cell lymphoma stage IIIBE while the second case of 38-year-old woman with relapsed non-hodgkin lymphoma. The first case showed a good outcome with improvement in consciousness 48 hours after stopping ifosfamide and thiamine, while the second case experienced tumor lysis syndrome, leading to the death of the patient.

Conclusion: Mechanism of ifosfamide-induced encephalopathy remains unclear, with the hypothesis from the neurotoxic effects of the resultant metabolite chloracetyldehide. Radiology examination of the brain and electroencephalography is required to rule out other differential diagnoses. Early recognition of adverse effects, followed by immediate discontinuation of ifosfamide, administration of therapy, such as methylene blue and/or thiamine, and supportive treatment usually produced good outcomes.


Keywords


encephalopathy, ifosfamide, lymphoma, thiamin

Full Text:

PDF

References


  1. Kataria P, Kendre P, Patel A. Ifosfamide-induced encephalopathy precipitated by aprepitant: A rarely manifested side effect of drug interaction. J Pharmacol Pharmacother. 2017;8(1):38–40. doi:10.4103/jpp.JPP_182_16
  2. Lo Y, Shen LJ, Chen WH, Dong YH, Wu FLL. Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis. Journal of the Formosan Medical Association. 2016;115(9):744–51. doi:10.1016/j.jfma.2015.07.016
  3. Vakiti A, Pilla R, Alhaj Moustafa M, Joseph JJ, Shenoy AG. Ifosfamide-Induced Metabolic Encephalopathy in 2 Patients With Cutaneous T-Cell Lymphoma Successfully Treated With Methylene Blue. J Investig Med High Impact Case Rep. 2018 4;6. doi:10.1177/2324709618786769
  4. Abahssain H, Moukafih B, Essangri H, Mrabti H, Meddah B, Guessous F, et al. Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?. J Oncology Pharmacy Practice. 2021;27(1):143–9. doi:10.1177/1078155220971843
  5. Patel PN. Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother. 2006;40(2):299–303. doi:10.1345/aph.1G114
  6. Hamilton JE, Alexander M, Kelleher FC. Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report. Clin Sarcoma Res. 2020;10(1):25 doi:10.1186/s13569-020-00147-3
  7. Tajino T, Kikuchi SI, Yamada H, Takeda A, Konno SI. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: Incidence, severity, and risk factors. Journal of Orthopaedic Science. 2010;15(1):104–11. doi:10.1007/s00776-009-1431-y
  8. Schmidt M, Benzler K, Lauer UM, Zender L, Hinterleitner C, Hinterleitner M. Inflammatory surrogate parameters for predicting ifosfamide-induced neurotoxicity in sarcoma patients. J Clin Med. 2022;11(19):5798. doi:10.3390/jcm11195798
  9. Séjourné A, Noal S, Boone M, Bihan C, Sassier M, Andrejak M, et al. Two cases of fatal encephalopathy related to ifosfamide: An adverse role of aprepitant?. Case Rep Oncol. 2014;7(3):669–72. doi:10.1159/000368184
  10. Lentz KL, Clark SM, Ayarza M, Liu B, Morgan KP, Wind LS, et al. Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. J Oncology Pharmacy Practice. 2020;26(2):406–12. doi:10.1177/1078155219859644
  11. Chain G, Kalia M, Kestenbaum K, Pappas L, Sechser-Perl A, Campino GA, et al. A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature. BMC Pediatr. 2022;22(1):76. doi:10.1186/s12887-022-03144-1
  12. Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S. Serotonin syndrome complicating treatment of ifosfamide neurotoxicity with methylene blue. Cancer Control. 2017;24(5):1073274817729070 doi:10.1177/1073274817729070
  13. Ibrahim H, Maksod SA, Khorshed M, Rady H, Alsisi A, Mohamed A, et al. Serotonin syndrome: a rare undiagnosed cause of hyperpyrexia. Egypt J Intern Med. 2023;35(1)1–4. doi:10.1186/s43162-023-00223-2
  14. Lozano M, Cid J, Müller TH. Plasma treated with methylene blue and light: clinical efficacy and safety profile. Transfus Med Rev. 2013;27(4):235–40. doi:10.1016/j.tmrv.2013.08.001
  15. NS D, I M. Encephalopathy associated with ifosfamide use in the treatment of patient with diffuse large B cell lymphoma. J Neurol Neurobiol. 2021;7(1)1–9. doi:10.16966/2379-7150.174




DOI: https://doi.org/10.15850/ijihs.v12.n2.3558

Article Metrics

Abstract view : 117 times
PDF - 38 times


 

This Journal indexed by

                   

 


Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License



View My Stats